2.07
-0.15 (-6.76%)
| Previous Close | 2.22 |
| Volume | 300,143 |
| Price / Earnings (Forward) | 13.06 |
| Price / Sales | 10.21 |
| Price / Book | 5.07 |
| 52 Weeks Range |
| Profit Margin | -184.04% |
| Operating Margin (TTM) | -1,956.57% |
| Diluted EPS (TTM) | -0.650 |
| Quarterly Revenue Growth (YOY) | -92.30% |
| Total Debt/Equity (MRQ) | 5.46% |
| Current Ratio (MRQ) | 1.53 |
| Operating Cash Flow (TTM) | 46.00 M |
| Levered Free Cash Flow (TTM) | 57.57 M |
| Return on Assets (TTM) | -17.07% |
| Return on Equity (TTM) | -43.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | AC Immune SA | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.8 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.35 |
Select this tab to load the latest available analysis.
|
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 38.01% |
| % Held by Institutions | 26.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wells Fargo & Company/Mn | 30 Jun 2026 | 1,004,041 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |